MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®. The new vaccine is indicated for active immunization to prevent COVID-19 caused ...

The new vaccine, mNexspike, is a step toward next-generation ... high risk of severe disease from COVID-19," Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug ...

Moderna has announced the FDA approval of a new, lower-dose messenger RNA (mRNA) vaccine against COVID-19, called mNEXSPIKE (mRNA-1283) (1). The product joins Moderna’s original COVID vaccine, ...

mNexspike is approved for older adults aged 65 and for individuals aged 12-64 with at least one underlying condition that puts them at high risk for severe COVID-19. Moderna had originally sought ...

The FDA has approved mNEXSPIKE (mRNA-1283), Moderna’s next-generation COVID-19 vaccine, for use in adults aged 65 years and older, as well as in individuals aged 12 to 64 years who have at least one ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

Rep. Marjorie Taylor Greene, R-Ga., slammed the U.S. Food and Drug Administration's move to give the green light to Moderna's mNEXSPIKE COVID-19 vaccine. "Not MAHA at all!!!," the congresswoman ...

The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike ...